NewsRoom Articles - Page 130 of 214

TuesdayDec 14, 2021 11:32 am

Review Finds Aerobic Exercise Benefits Fibromyalgia Patients

A review published in the “Cochrane Library” stated that aerobic exercise may be beneficial to patients suffering from fibromyalgia. Aerobic exercises such as swimming and walking are known to improve cardiovascular conditioning, in addition to other benefits. These include helping control weight and blood sugar, lowering an individual’s blood pressure, improving circulation and strengthening the heart. The systematic literature review was conducted by researchers from the Norwegian Institute of Public Health in Oslo, led by Julia Bidonde. Fibromyalgia is a disorder characterized by musculoskeletal pain that is normally accompanied by mood and memory issues, sleep issues and fatigue. Experts believe…

MondayDec 13, 2021 9:56 am

Pandemic Exposes Extent of Kids’ Mental Health Issues

The coronavirus pandemic has not only affected economies around the globe but also impacted the mental health of both grown-ups and children significantly. Behavioral disorders, anxiety and depression are among the leading causes of disability and illness among adolescents. Data from the World Health Organization (“WHO”) shows that one in every seven children between the ages of 10 to 19 experiences a mental disorder, which makes up about 13% of the worldwide burden of illness. Adolescents with mental health issues are especially vulnerable to risk-taking behaviors, educational difficulties, stigma, discrimination and social exclusion. Harvard professor Karestan Koenen notes that the…

FridayDec 10, 2021 12:58 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Discusses Psychedelics Research, Life Sciences Focus, at Key Industry Conferences

MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM The global digital therapeutics market is valued at $3.4 billion and is projected to reach…

FridayDec 10, 2021 9:33 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

FridayDec 10, 2021 9:30 am

Study Finds Type 2 Diabetes More Prevalent in Those with Psychiatric Disorders

Diabetes is a common disease, with figures showing that about 6% of the global population is afflicted by the ailment. Since 1990, rates of the disease have been increasing, with estimates showing that this trend is expected to continue for at least two more decades. Now new research has found that type 2 diabetes is more common in individuals with psychiatric disorder, in comparison with other people. The research was carried out by a team of researchers from the University of Southern Denmark, led by Nanna Lindekilde of the school’s psychology department. Its findings were reported in “Diabetologia.” Psychiatric disorders…

ThursdayDec 09, 2021 1:36 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:26 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…

ThursdayDec 09, 2021 9:30 am

Data Analytics Show Decline in Cancer Screening in 2020

Most patients put off going to the doctor or skipped undergoing checkups because of the coronavirus pandemic last year. Despite infection cases dropping and vaccine rollout, data analytics still show a considerable drop in CT imaging for cancer. Researchers from Harvard Medical School and Massachusetts General Hospital conducted an analysis of CT exams for cancer that were conducted last year, both during the precoronavirus phase and the peak coronavirus phase, as well as in the post-coronavirus peak phase. The researchers studied the care delivered to patients via imaging as well as the CT volume, finding that during the disease’s peak,…

WednesdayDec 08, 2021 9:30 am

Virtual Care: How Small Businesses Can Use It to Save Time, Money

Virtual healthcare has become the new normal since the coronavirus pandemic began last year, with McKinsey & Company finding that the popularity of virtual primary care increased substantially in April 2020. Despite the potential to improve healthcare plans and reach more people, there still exist considerable barriers to the extensive adoption of virtual care. These include discomfort toward technology among individuals, especially older people, and the perception that the technology used is not secure. For the use of telehealth to continue growing, these barriers need to be addressed. A separate survey also found that virtual care is convenient and can…

TuesdayDec 07, 2021 11:13 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year

2021 marked Mydecine’s patent application for its MYCO-003 drug candidate It also marked notable clinical trials on various aspects, including smoking cessation Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics These milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), since its inception in 2020, has been aiming to transform the treatment of mental health disorders and addiction through biotechnology. The company…